Q3 2025 Vivos Therapeutics Inc Earnings Call Transcript
Key Points
- Revenue increased by 76% to $6.8 million in Q3 2025 compared to Q3 2024, reflecting successful integration of the Sleep Center of Nevada (SCN).
- The acquisition of SCN has led to a significant increase in OSA sleep testing services revenue, contributing $2.2 million in Q3 2025.
- Vivos Therapeutics Inc (VVOS) has received FDA clearance for its appliances to treat severe OSA, allowing for expanded treatment options.
- The strategic pivot to acquiring medical sleep practices is showing positive results, with increased revenue and potential for further growth.
- The company has secured $14.2 million in net cash from financing activities, providing financial stability for future growth initiatives.
- Net loss increased to $5.4 million in Q3 2025, reflecting higher costs associated with the business model pivot.
- General and administrative expenses rose by 42% to $19.2 million for the nine months ended September 30, 2025, due to increased operational costs.
- The company is experiencing higher costs related to the integration of SCN, including staff compensation and software expenses.
- There is a delay in revenue realization due to the time required for licensing and credentialing new providers, impacting short-term financial performance.
- Vivos Therapeutics Inc (VVOS) is still in the process of optimizing its operations to better manage costs and improve gross margins.
Good day everyone, and welcome to the Vivos third quarter 2025 conference call. (Operator Instructions). This conference call is being recorded, and the replay of today's call will be available on the investor relations section of Vivos website and will remain posted there for the next 30 days. I will now hand the call over to Brad Amman, Chief Financial Officer, for your introductions and reading of the Safe harbor statements. Please go ahead sir.
Thank you, Konstantine. Hello everyone, and welcome to our conference call. A copy of our earnings press release is available on the investor relations section of our website at www.vivos.com. With me on the call today is Kirk Huntsman, Vivos Chairman and Chief Executive Officer. Today we'll review the financial results for the third quarter of 2025, as well as more recent developments and Vivos plans for the rest of 2025 and beyond. Following these formal remarks, we'll be happy to take
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
